Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum

British Journal of Dermatology, Supplement

Volumn 149, Issue 66, 2003, Pages 15-19

  Hengge, U R ^a   Cusini, M ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Human papillomavirus; Imiquimod; Molluscum contagiosum; Topical immunomodulators

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; BLEOMYCIN; CHLOROACETIC ACID; CIDOFOVIR; CIMETIDINE; DIPHENCYPRONE; FLUOROURACIL; IMIQUIMOD; INTERFERON; PODOPHYLLOTOXIN; RETINOL; SALICYLIC ACID; SILVER NITRATE;

BURNING SENSATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CONDYLOMA ACUMINATUM; CONFERENCE PAPER; CUTANEOUS WART; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; EROSION; ERYTHEMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MOLLUSCUM CONTAGIOSUM; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VERRUCA VULGARIS; WART VIRUS;

EID: 0346059383     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0366-077x.2003.05623.x     Document Type: Conference Paper

References (33)

1. Wagner TL, Horton VL, Carlson GL et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers imiquimod. S-27609 and S-28463. Cytokine 1997; 9: 837-45.
2. Imbertson LM, Beaurline JM, Couture AM et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110: 734-9.
3. Wagner TL, Ahonen CL, Couture AM et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers. R-848 and imiquimod. Cell Immunol 1999; 191: 10-19.
4. Kono T, Kondo S, Pastore S et al. Effects of a novel topical immunomodulator, imiquimod, on keratlnocyte cytokine gene expression. Lymphokine Cytokine Res 1994; 13: 71-6.
5. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2002; 51 (RR 6): 1-78.
6. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epldemiol Rev 1988; 10: 122-63.
7. Gissmann L. Papillomaviruses and human oncogenesis. Curr Opin Genet Dev 1992; 2: 97-102.
8. Fazel N, Wilczynski S, Lowe L, Su LD. Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Dermatol Clin 1999; 17: 521-36.
9. Massing AM, Epstein WL. Natural history of warts: a 2-year study. Arch Dermatol 1963; 87: 306-10.
10. Gissmann L. Immunologic responses to human papillomavirus infection. Obstet Gynecol Clin North Am 1996; 23: 625-39.
11. Coleman N, Birley HD, Renton AM et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102: 768-74.
12. Phelps WC, Alexander KA. Antiviral therapy for human papillomaviruses: rationale and prospects. Ann Intern Med 1995; 123: 368-82.
13. Hengge UR. Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators - progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001; 1: 189-98.
14. Edwards L, Ferency A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134: 25-30.
15. Tyring SK, Arany I, Stanley MA et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect Dis 1998; 178: 551-5.
16. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38: 230-9.
17. Gollnick H, Barasso R, Jappe U et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001; 12: 22-8.
18. Wagman FA, Estape RE, Angioli R, Penalver MA. Self-administered topical 5% imiquimod cream for external anogenital warts in adolescent girls. Obstet Gynecol 2001; 97: 14-19.
19. Kaspari M, Gutzmer R, Kaspari T, Kapp A, Broderson JP. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Br J Dermatol 2002; 147: 757-9.
20. Carrasco D, vander Straten M, Tyring SK. Treatment of anogenital warts with imiquimod 5% cream followed by surgical resection of residual lesions. J Am Acad Dermatol 2002; 47: S212-16.
21. Bishop PE, McMillan A, Fletcher S. An immunohistological study of spontaneous regression of condylomata acuminata, Genitourin Med 1990; 66: 79-81.
22. Arany I, Tyring SK, Stanley MA et al. Enhancement of innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999; 43: 55-63.
23. Hengge UR, Franz B, Goos M. Decline of infectious skin manifestations in the era of highly active antiretroviral therapy. AIDS 2000; 14: 1069-70.
24. Arrese J, Paquet P, Claessens N, Pierard-Franchimont C, Pierard G. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol 2001; 28: 131-4.
25. Hengge UR, Esser S, Schultewolter T et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143: 1026-31.
26. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online J 2001; 7: 20-3.
27. Goldstein D, Hertzog P, Tomkinson E et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998; 178: 858-61.
28. Gilson RJ, Shupack JL, Friedman-Kien AE et al. A randomized, controlled, safety study using imiqutmod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS 1999; 13: 2397-404.
29. Liota EE, Smith KJ, Buckley R, Menon P, Skelton H. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000; 4: 76-82.
30. Weisshaar E, Gollnick H. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venereol 2000; 80: 306-7.
31. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol 2001; 137: 14-16.
32. Cusini M, Salmaso F, Zerboni R et al. 5% imiquimod cream for external anogenital warts in HIV-infected patients. International J STD and AIDS, in press.
33. Saiag P, Bourgault-Villada I, Pavlovic M et al. Efficacy of imiquimod on external anogenital warts in HIV-infected patients previously treated by highly active antlretrovlral therapy. AIDS 2002; 16: 1438-40.